Cargando…

Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience

OBJECTIVE: In this study, we retrospectively analyzed the clinical outcome, treatment responses, infectious complications, and survival rates of 71 hairy cell leukemia (HCL) cases. MATERIALS AND METHODS: Sixty-seven patients received a first-line treatment and 2-chlorodeoxyadenosine (cladribine-2-Cd...

Descripción completa

Detalles Bibliográficos
Autores principales: Öngören, Şeniz, Eşkazan, Ahmet Emre, Berk, Selin, Elverdi, Tuğrul, Salihoğlu, Ayşe, Ar, Muhlis Cem, Başlar, Zafer, Aydın, Yıldız, Tüzüner, Nükhet, Soysal, Teoman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774373/
https://www.ncbi.nlm.nih.gov/pubmed/29199176
http://dx.doi.org/10.4274/tjh.2016.0443
_version_ 1783293747099860992
author Öngören, Şeniz
Eşkazan, Ahmet Emre
Berk, Selin
Elverdi, Tuğrul
Salihoğlu, Ayşe
Ar, Muhlis Cem
Başlar, Zafer
Aydın, Yıldız
Tüzüner, Nükhet
Soysal, Teoman
author_facet Öngören, Şeniz
Eşkazan, Ahmet Emre
Berk, Selin
Elverdi, Tuğrul
Salihoğlu, Ayşe
Ar, Muhlis Cem
Başlar, Zafer
Aydın, Yıldız
Tüzüner, Nükhet
Soysal, Teoman
author_sort Öngören, Şeniz
collection PubMed
description OBJECTIVE: In this study, we retrospectively analyzed the clinical outcome, treatment responses, infectious complications, and survival rates of 71 hairy cell leukemia (HCL) cases. MATERIALS AND METHODS: Sixty-seven patients received a first-line treatment and 2-chlorodeoxyadenosine (cladribine-2-CdA) was administered in 31 cases, 19 patients received interferon-alpha (INF-α), splenectomy was performed in 16 cases, and rituximab was used in one. RESULTS: Although the highest overall response rate (ORR) was observed in patients receiving 2-CdA upfront, ORRs were comparable in the 2-CdA, INF-α, and splenectomy subgroups. Relapse rates were significantly lower in patients who received first-line 2-CdA. The progression-free survival (PFS) rate with 2-CdA was significantly higher than in patients with INF-α and splenectomy, but we found similar overall survival rates with all three upfront treatment modalities. Infections including tuberculosis were a major problem. CONCLUSION: Although purine analogues have improved the ORRs and PFS, there is still much progress to make with regard to overall survival and relapsed/refractory disease in patients with HCL.
format Online
Article
Text
id pubmed-5774373
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-57743732018-01-30 Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience Öngören, Şeniz Eşkazan, Ahmet Emre Berk, Selin Elverdi, Tuğrul Salihoğlu, Ayşe Ar, Muhlis Cem Başlar, Zafer Aydın, Yıldız Tüzüner, Nükhet Soysal, Teoman Turk J Haematol Research Article OBJECTIVE: In this study, we retrospectively analyzed the clinical outcome, treatment responses, infectious complications, and survival rates of 71 hairy cell leukemia (HCL) cases. MATERIALS AND METHODS: Sixty-seven patients received a first-line treatment and 2-chlorodeoxyadenosine (cladribine-2-CdA) was administered in 31 cases, 19 patients received interferon-alpha (INF-α), splenectomy was performed in 16 cases, and rituximab was used in one. RESULTS: Although the highest overall response rate (ORR) was observed in patients receiving 2-CdA upfront, ORRs were comparable in the 2-CdA, INF-α, and splenectomy subgroups. Relapse rates were significantly lower in patients who received first-line 2-CdA. The progression-free survival (PFS) rate with 2-CdA was significantly higher than in patients with INF-α and splenectomy, but we found similar overall survival rates with all three upfront treatment modalities. Infections including tuberculosis were a major problem. CONCLUSION: Although purine analogues have improved the ORRs and PFS, there is still much progress to make with regard to overall survival and relapsed/refractory disease in patients with HCL. Galenos Publishing 2017-12 2017-12-01 /pmc/articles/PMC5774373/ /pubmed/29199176 http://dx.doi.org/10.4274/tjh.2016.0443 Text en © Turkish Journal of Hematology, Published by Galenos Publishing. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Öngören, Şeniz
Eşkazan, Ahmet Emre
Berk, Selin
Elverdi, Tuğrul
Salihoğlu, Ayşe
Ar, Muhlis Cem
Başlar, Zafer
Aydın, Yıldız
Tüzüner, Nükhet
Soysal, Teoman
Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience
title Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience
title_full Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience
title_fullStr Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience
title_full_unstemmed Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience
title_short Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience
title_sort retrospective evaluation of hairy cell leukemia patients treated with three different first-line treatment modalities in the last two decades: a single-center experience
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774373/
https://www.ncbi.nlm.nih.gov/pubmed/29199176
http://dx.doi.org/10.4274/tjh.2016.0443
work_keys_str_mv AT ongorenseniz retrospectiveevaluationofhairycellleukemiapatientstreatedwiththreedifferentfirstlinetreatmentmodalitiesinthelasttwodecadesasinglecenterexperience
AT eskazanahmetemre retrospectiveevaluationofhairycellleukemiapatientstreatedwiththreedifferentfirstlinetreatmentmodalitiesinthelasttwodecadesasinglecenterexperience
AT berkselin retrospectiveevaluationofhairycellleukemiapatientstreatedwiththreedifferentfirstlinetreatmentmodalitiesinthelasttwodecadesasinglecenterexperience
AT elverditugrul retrospectiveevaluationofhairycellleukemiapatientstreatedwiththreedifferentfirstlinetreatmentmodalitiesinthelasttwodecadesasinglecenterexperience
AT salihogluayse retrospectiveevaluationofhairycellleukemiapatientstreatedwiththreedifferentfirstlinetreatmentmodalitiesinthelasttwodecadesasinglecenterexperience
AT armuhliscem retrospectiveevaluationofhairycellleukemiapatientstreatedwiththreedifferentfirstlinetreatmentmodalitiesinthelasttwodecadesasinglecenterexperience
AT baslarzafer retrospectiveevaluationofhairycellleukemiapatientstreatedwiththreedifferentfirstlinetreatmentmodalitiesinthelasttwodecadesasinglecenterexperience
AT aydınyıldız retrospectiveevaluationofhairycellleukemiapatientstreatedwiththreedifferentfirstlinetreatmentmodalitiesinthelasttwodecadesasinglecenterexperience
AT tuzunernukhet retrospectiveevaluationofhairycellleukemiapatientstreatedwiththreedifferentfirstlinetreatmentmodalitiesinthelasttwodecadesasinglecenterexperience
AT soysalteoman retrospectiveevaluationofhairycellleukemiapatientstreatedwiththreedifferentfirstlinetreatmentmodalitiesinthelasttwodecadesasinglecenterexperience